Article Text

Download PDFPDF
Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy
  1. P Di Napoli1,
  2. A A Taccardi1,
  3. A Barsotti2
  1. 1Department of Cardiology, Intensive Care Unit, Casa di Cura Villa Pini d’Abruzzo, Chieti, Italy
  2. 2Department of Internal Medicine, University of Genoa, Genoa, Italy
  1. Correspondence to:
    Dr Pericle Di Napoli
    Dipartimento di Cardiologia-UTIC, Casa di Cura Villa Pini d’Abruzzo, Via dei Frentani 228, 66100 Chieti, Italy;


Objective: To investigate the long term effects of trimetazidine in patients with dilated ischaemic cardiomyopathy. The effects of trimetazidine on left ventricular function as well as its tolerability profile and potential anti-inflammatory effects were studied.

Design: 61 patients were randomly assigned either to receive trimetazidine (20 mg thrice daily) in addition to their conventional treatment or to continue their usual drug treatment for 18 months. Patients were evaluated at baseline and at 6, 12, and 18 months with a clinical examination, echocardiography, and biochemical analysis (C reactive protein).

Results: Trimetazidine added to the usual treatment significantly improved the patients’ functional status (assessed by New York Heart Association functional class). The functional improvement of trimetazidine treated patients was associated with a significant increase in left ventricular ejection fraction (30 (6)%, 32 (8)%, 38 (7)%, and 37 (6)% v 31 (8)%, 30 (7)%, 28 (6)%, and 26 (9)% in control patients at baseline and at 6, 12, and 18 months, respectively) and with a significant effect on ventricular remodelling. C reactive protein plasma concentrations remained stable throughout the study in patients receiving trimetazidine (2.5 (1.0), 2.7 (2.0), 2.7 (3.0), and 3.0 (2.0) mg/l at baseline and at 6, 12, and 18 months, respectively) but increased significantly in the control group (2.4 (1.0), 3.4 (1.2), 6.0 (4.0), and 7.0 (5.0) mg/l, respectively). No significant adverse event or changes in clinical or biochemical parameters were detected.

Conclusion: Treatment with trimetazidine added to the usual treatment for up to 18 months was well tolerated and induced a functional improvement in patients with dilated cardiomyopathy. Trimetazidine treatment was associated with a significant improvement of left ventricular function and the remodelling process. Results also suggest that the inflammatory response was limited in patients treated with trimetazidine.

  • ACE, angiotensin converting enzyme
  • LV, left ventricular
  • LVEF, left ventricular ejection fraction
  • NYHA, New York Heart Association
  • randomised study
  • trimetazidine
  • ischaemic dilated cardiomyopathy
  • cardioprotection
  • inflammatory process

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.